Get started
Author

Nils L. Visser

Observed names: N.L. Visser, Nils L Visser, Nils Visser, Visser, N., Visser, Nils
ORCID: 0009-0006-6512-4348
Observed ORCID: 0009-0006-6512-4348
OpenAlex ID: A5041304367
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
2015 · Marc J.M. Bonten, Susanne M. Huijts, et al. · New England Journal of Medicine · 1,236
PDF
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
2019 · David W. Vredevoogd, Thomas Kuilman, et al. · Cell · 259
PDF
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis
2013 · Christophe J. Desmet, Tristan Gallenne, et al. · Proceedings of the National Academy of Sciences · 172
Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature
2011 · Ingar Seemann, Karen Gabriels, et al. · Radiotherapy and Oncology · 137
Massive reshaping of genome–nuclear lamina interactions during oncogene-induced senescence
2017 · Christelle Lenain, Carolyn A. de Graaf, et al. · Genome Research · 88
PDF
Local heart irradiation of ApoE−/− mice induces microvascular and endocardial damage and accelerates coronary atherosclerosis
2012 · Karen Gabriels, Saske Hoving, et al. · Radiotherapy and Oncology · 81
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade
2021 · Julia Boshuizen, Nora Pencheva, et al. · Cancer Research · 68
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
2022 · Georgi Apriamashvili, David W. Vredevoogd, et al. · Nature Communications · 59
PDF
Irradiation induces different inflammatory and thrombotic responses in carotid arteries of wildtype C57BL/6J and atherosclerosis-prone ApoE−/− mice
2012 · Saske Hoving, Sylvia Heeneman, et al. · Radiotherapy and Oncology · 49
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells
2022 · Zhengkui Zhang, Xiangjun Kong, et al. · Cell Reports Medicine · 47
PDF
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
2020 · David W. Vredevoogd, Thomas Kuilman, et al. · Cell · 45
PDF
Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer
2017 · Tristan Gallenne, Kenneth N. Ross, et al. · Oncotarget · 41
PDF
Multimodal Interventional Molecular Imaging of Tumor Margins and Distant Metastases by Targeting αvβ3 Integrin
2012 · Anton Bunschoten, Tessa Buckle, et al. · ChemBioChem · 41
Tumour-reactive heterotypic CD8 T cell clusters from clinical samples
2025 · Sofía Ibáñez-Molero, Johanna Veldman, et al. · Nature · 21
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness
2024 · Chun-Pu Lin, Pierre L. Levy, et al. · Cancer Cell · 20
PDF
TSC2 regulates tumor susceptibility to TRAIL‐mediated T‐cell killing by orchestrating mTOR signaling
2023 · Chun-Pu Lin, Joleen J.H. Traets, et al. · The EMBO Journal · 19
PDF
Thalidomide is not able to inhibit radiation-induced heart disease
2013 · Saske Hoving, Ingar Seemann, et al. · International Journal of Radiation Biology · 19
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
2024 · David W Vredevoogd, Georgi Apriamashvili, et al. · Journal for ImmunoTherapy of Cancer · 6
PDF
Loss of Ubiquitin Ligase STUB1 Amplifies IFNγ-R1/JAK1 Signaling and Sensitizes Tumors to IFNγ
2020 · Georgi Apriamashvili, David W. Vredevoogd, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
PDF
Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2 -Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
2026 · Thijs Jalving, Carine Dufau, et al. · Cancer Research · 1
Supplementary Figure S3 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
2026 · Thijs Jalving, Carine Dufau, et al.
Data from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
2026 · Thijs Jalving, Carine Dufau, et al.
Supplementary Figure S4 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
2026 · Thijs Jalving, Carine Dufau, et al.
Supplementary Table S3 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
2026 · Thijs Jalving, Carine Dufau, et al.
Supplementary Table S5 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
2026 · Thijs Jalving, Carine Dufau, et al.
Works count: 43
Citation count: 2,408
H-index: 17
I10-index: 17
Year
Topic
Type